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Abstract 
Background: HIV-1 typically develops resistance to any single antiretroviral agent. Combined anti-retroviral therapy 
to reduce drug-resistance development is necessary to control HIV-1 infection. Here, to assess the utility of a combina-
tion of antibody and fusion inhibitor treatments, we investigated the potency of monoclonal antibodies at neutraliz-
ing HIV-1 variants that are resistant to fusion inhibitors.
Results: Mutations that confer resistance to four fusion inhibitors, enfuvirtide, C34, SC34, and SC34EK, were intro-
duced into the envelope of HIV-1JR-FL, a CCR5-tropic tier 2 strain. Pseudoviruses with these mutations were prepared 
and used for the assessment of neutralization sensitivity to an array of antibodies. The resulting neutralization data 
indicate that the potencies of some antibodies, especially of those against the CD4 binding site, V3 loop, and mem-
brane-proximal external region epitopes, were increased by the mutations in gp41 that conferred resistance to the 
fusion inhibitors. C34-, SC34-, and SC34EK-resistant mutants showed more sensitivity to monoclonal antibodies than 
enfuvirtide-resistant mutants. An analysis of C34-resistant mutations revealed that the I37K mutation in gp41 HR1 is a 
key mutation for C34 resistance, low infectivity, neutralization sensitivity, epitope exposure, and slow fusion kinetics. 
The N126K mutation in the gp41 HR2 domain contributed to C34 resistance and neutralization sensitivity to anti-
CD4 binding site antibodies. In the absence of L204I, the effect of N126K was antagonistic to that of I37K. The results 
of a molecular dynamic simulation of the envelope trimer confirmation suggest that an I37K mutation induces the 
augmentation of structural fluctuations prominently in the interface between gp41 and gp120. Our observations 
indicate that the “conformational unmasking” of envelope glycoprotein by an I37K mutation is one of the mechanisms 
of neutralization sensitivity enhancement. Furthermore, the enhanced neutralization of C34-resistant mutants in vivo 
was shown by its high rate of neutralization by IgG from HIV patient samples.
Conclusions: Mutations in gp41 that confer fusion inhibitor resistance exert enhanced sensitivity to broad neutral-
izing antibodies (e.g., VRC01 and 10E8) and other conventional antibodies developed in HIV-1 infected patients. 
Therefore, next-generation fusion inhibitors and monoclonal antibodies could be a potential combination for future 
regimens of combined antiretroviral therapy.
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Background
Combined anti-retroviral therapy (ART) has been effec-
tive at suppressing HIV-1 replication, but ART is unable 
to cure HIV-1 infection and demands a lifetime invest-
ment [1, 2]. Additionally, the long-term application of 
ART is associated with several adverse effects and the 
emergence of drug resistance [3–5]. To avoid these issues, 
the development of a new ART combination that targets 
different steps of viral replication other than reverse tran-
scription, integration, and protease processing of viral 
protein should be pursued. For example, HIV-1 entry 
inhibitors could be an attractive target for investigation.
Stepwise knowledge regarding viral entry, which 
involves attachment with CD4, binding with a co-recep-
tor (CCR5 or CXCR4), and fusion with the target cell, 
has allowed to develop diverse antiviral agents, such as 
N-phenyl-N-piperidin-4-yl-oxalamide, BMS-663068, 
AMD3100, Maraviroc, and Cenicriviroc [6–8]. Among 
entry inhibitors, the structural features of HIV-1 fusion 
machinery in gp41 have helped to develop fusion inhibi-
tors. During HIV-1 entry, after co-receptor binding, con-
formational changes trigger the formation of a six-helix 
bundle composed of an N-terminal heptad repeat (HR1) 
and a C-terminal heptad repeat (HR2). Fusion inhibitors 
are peptides corresponding to the HR1 or HR2 region 
that bind with another counterpart and inhibit the for-
mation of the six-helix complex. The classic fusion inhib-
itors are HR2-derived peptides, such as enfuvirtide (ENF) 
and C34, among which only ENF has received FDA 
approval for clinical application [6]. ENF has less toxic-
ity, and its co-administration with tipranavir, darunavir, 
and maraviroc significantly improved response rates [9]. 
The major obstacle for the therapeutic application of 
ENF is the rapid development of resistance, especially 
when it is delivered without a strong regimen. Notably, 
a single point mutation can emerge within several weeks 
after ENF administration that can give rise to drug resist-
ance [10–13]. In contrast, C34 imposes a relatively high 
genetic barrier for resistance development in  vitro [14]. 
Derivatives of C34 peptides have been developed with 
better solubility, enhanced α-helicity, enhanced activ-
ity, and a bigger barrier to resistance development [15]. 
These C34 derivatives include SC34 and SC34EK, which 
are still under pre-clinical evaluation [16, 17].
Within a few weeks of detectable HIV-1 viremia, an 
antibody response develops in infected persons [18]. 
The antibodies developed against HIV-1 envelope have 
the potential to target all steps of viral entry. A range 
of recently discovered broad neutralizing antibodies 
(bnAbs) indicates the possibility of antibody-mediated 
immunotherapy, which could inhibit diverse HIV-1 sub-
types. Several of these monoclonal antibodies (MAbs) 
were found to control viral infection in humanized 
mice and in macaques [19, 20]. Recently, clinical tri-
als in HIV-1-infected patients have shown encouraging 
effects for antibody-mediated suppression of viral rep-
lication in  vivo. Antibodies such as 3BNC117, VRC01, 
and KD247 were well tolerated in human trials and 
each maintained a 1–2.5-log reduction of viral load for 
30–100 days [21–24]. However, like all other anti-retro-
viral drugs, the single administration of an antibody is 
prone to resistance development. Hence, combination 
strategies are necessary.
Here, we report enhanced neutralization sensitivity to 
an array of neutralizing antibodies, including bnAbs, due 
to mutations in gp41 that confer C34, SC34, or SC34EK 
resistance. A decade ago, Reeves et al. reported changes 
in the neutralization sensitivity of the ENF-resistant 
mutants against some neutralizing antibodies [25]. In the 
present study, we report that recently developed bnAbs, 
such as VRC01 and 10E8, can neutralize fusion inhibitor-
resistant mutants efficiently. Furthermore, conventional 
antibodies against the CD4 binding site (CD4bs) and 
V3 loop become potent against drug-resistant mutants 
of HIV-1 compared with their effects against wild-type 
(WT) virus. Along with neutralization sensitivity, we 
have identified a mutation (I37K) in the gp120–gp41 
interactive region of gp41 HR1 that has a global impact 
on the different antigenic sites on the HIV-1 envelope. 
The results will add new insights to our understanding of 
the HIV-1 envelope and may help to select antibody part-
ners for combined therapy with fusion inhibitors.
Methods
Patient samples
Plasma samples from HIV-1-infected patients, including 
patient KTS376 described in our previous study, were 
collected and purified using protein A-Sepharose (Affi-
gel Protein A; Bio-Rad, Hercules, CA, USA) [26].
Cells, plasmids, and antibodies
TZM-bl [27] and 293T [28] cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM; Sigma, St. 
Louis, MO, USA) supplemented with 10  % heat-inacti-
vated fetal calf serum (FCS; Thermo Scientific, Waltham, 
MA). The generation of antibodies 49G2, 82D5, 42F9, 
0.5γ, KD-247, 16G6, 916B2, and 4E9C were previously 
reported by Ramirez Valdez et  al. [26]. The antibody 
2E8S34 was similarly isolated by EBV transformation 
from patient KTS376 [26]. Plasmids for the expression 
of heavy and light chains of bnAb VRC01 were obtained 
through the NIH AIDS Reagent Program, Division of 
AIDS, NIAID, NIH from Dr. J. Mascola [22]. bnAb b12 
[29] was kindly provided from Dr. D. Burton. Heavy and 
light chain genes of 10E8 [30] and 2G12 [31] were synthe-
sized from their amino acid sequences (GeneArt Strings 
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DNA Fragments; Invitrogen, Carlsbad, CA, USA) and 
inserted into expression vectors as described previously 
[26]. Soluble CD4 was purchased commercially (sCD4, 
R&D systems, Inc., Minneapolis, MN, USA). Anti-mem-
brane-proximal external region (MPER) antibodies 4E10 
[32] and 2F5 [33] were purchased commercially (Poly-
mun Scientific, GmbH, Klosterneuburg, Austria). Fusion 
inhibitors, C34, SC34, SC34EK, and ENF were synthe-
sized following the methods described in a previous 
report [16].
Construction of recombinant plasmids and mutants
Plasmids to express mutant envelopes, pCXN-JR-FLV38A, 
pCXN-JR-FLQ40H, pCXN-JR-FLN43D, pCXN-JR-FLC34r 
(I37K/N126K/L204I), pCXN-JR-FLSC34r (I37K/R46K/
Q52R/Q56R/N126K/S138A/E151K/K154N/L204I/
L210F), and pCXN-JR-FLSC34EKr (Q41R/N43K/A96D/
N126K/V182I/P203S/L204I/H258Q/A312T) were con-
structed by oligonucleotide-based site-directed mutagen-
esis with pCXN-JR-FL (kindly provided by Dr. Y. Maeda, 
Kumamoto University), which express WT JR-FL enve-
lope [15]. Single and double mutants of C34r muta-
tions, I37K, N126K, and L204I, were constructed by PCR 
and subsequent homologous recombination using the 
GeneArt® seamless cloning an assembly enzyme mix 
(Invitrogen).
The plasmid expressing both the JR-FL envelope 
and IRES2-EGFP, pCXN-JR-FL-IRES2-EGFP was con-
structed by inserting the IRES2-EGFP fragment, which 
was amplified by primers 5IRES2 (5′-GGTGGGAGCAG-
TATCTCGAGGATCCGCCCCTC-3′) and 3EGFP2 
(5 ′ -CG G C T T T TCC AG GTC T T TAC T TGTAC A-
GCTCG-3′) using pLp-IRES2-EGFP [34] as the template, 
into the XhoI site of pCXN-JR-FL. Plasmids to express 
the other envelope mutants and EGFP (enhanced green 
fluorescent protein) were similarly constructed and used 
for flow cytometry studies.
Pseudovirus preparation
Pseudoviruses were prepared as described previously 
[26]. Briefly, exponentially dividing 293T cells were 
transfected with 1.3 µg of pSG3ΔEnv and 5.2 µg of enve-
lope expression vector using Lipofectamine 2000 trans-
fection reagent (Invitrogen, Life Technologies, Carlsbad, 
CA, USA) in six-well cell culture plates. After 48  h of 
transfection, pseudovirus-containing supernatants were 
harvested, filtered through a 0.2-µm pore-size filter, 
and stored at −80  °C until further use. The median tis-
sue culture infectious dose (TCID50) of each pseudovi-
rus was determined using TZM-bl cells. The amount 
of p24 was determined by using a commercial enzyme-
linked immunosorbent assay (ELISA) kit (ZeptoMetrix 
Corporation, Buffalo, NY) according to the manufactur-
er’s instructions.
Analysis of sensitivity to antibodies, sCD4, and fusion 
inhibitors
The neutralization sensitivities of pseudoviruses were 
measured following a previously described protocol [35]. 
Briefly, serial dilutions of MAbs, sCD4, or fusion inhibi-
tors in DMEM with 10 % FCS were placed in 96-well cell 
culture plates in triplicate. After dilution, 200 TCID50 of 
each respective pseudovirus suspension was added to 
each well. Each plate had triplicates of the respective viral 
control (without any inhibitor) and a cell control (with-
out any virus). The virus-MAb mixture was incubated 
for 1 h (37  °C, 5 % CO2). After incubation, 104 TZM-bl 
cells in suspension with 30  µg/mL of DEAE-dextran 
were added to each well and incubated for 48  h (37  °C, 
5  % CO2). Finally, the cells were washed, lysed, and the 
firefly luciferase activity was measured using a Galacto-
star system (Life Technologies, Carlsbad, CA, USA). The 
percent inhibition by MAb, sCD4, or fusion inhibitor was 
determined by comparing the RLU in the presence and 
absence of an inhibitor. Each assay was repeated at least 
three times and validated according to the pass/fail crite-
ria for TZM-bl cell based neutralization assay described 
by Sarzotti-Kelsoe et al. [36].
Antibody‑envelope binding assays
The binding of MAbs to the HIV-1 envelope that was 
expressed on transiently transfected 293T cells was ana-
lyzed by flow cytometry. One day before transfection, 
293T cells were cultured (2 × 106 cells/well) in six-well 
plates. When the cell growth reached about 60–70 % con-
fluency, 1 µg of plasmid expressing both the envelope and 
EGFP was transfected using Lipofectamine 2000 transfec-
tion reagent (Invitrogen). After 48  h of transfection, the 
cells were washed with phosphate-buffered saline (PBS) 
and harvested with 0.05  % trypsin and resuspended in 
PBS containing 0.2 % BSA. For each envelope mutant, 105 
cells were stained with the respective primary antibody for 
30  min at room temperature (RT). After incubation, the 
cells were washed twice with PBS containing 0.2  % BSA 
and incubated with allophycocyanin-conjugated AffiniPure 
F(ab’)2 Fragment Goat Anti-Human IgG (H + L) (Jackson 
ImmunoResearch, West Grove, PA, USA) for 15 min at RT. 
Cells were fixed with PBS containing 10  % formalin and 
analyzed using the FACSCalibur system (Becton–Dickin-
son, Franklin Lakes, NJ, USA). After gating on the EGFP+ 
cells, the mean fluorescence intensity (MFI) for each sam-
ple was calculated using FlowJo (TreeStar, San Carlos, CA, 
USA). Each mutant was stained with 2G12 (which targets 
the glycan structure on HIV-1 envelope) for normalization, 
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and the antibody–envelope binding was represented by the 
antibody MFI/2G12 MFI ratio [37].
Comparison of envelope content on virion surfaces
To compare the envelope content per virion, we deter-
mined the amount of p24 and gp120 in a pseudovirus 
stock by ELISA. As negative control, delta envelope pseu-
dovirus (pSG3ΔEnv only) was used in the experiment. 
Pseudovirus stocks were centrifuged at 13,200  rpm for 
90 min at 4 °C, and the viral pellets were resuspended in 
1 mL of PBS and centrifuged again under the same condi-
tions. Finally, the viral pellets were lysed with Tris-buff-
ered saline containing 1 % empigen (Sigma). The amount 
of p24 protein was determined with an ELISA kit (Zep-
toMetrix Corporation, Buffalo, NY, USA) as described 
above. For determination of the amount of gp120, ELISA 
plates were coated with 10 µg/ml of anti-V3 specific anti-
body 0.5γ in carbonate-bicarbonate buffer overnight at 
4 °C. The plate was washed with ELISA wash buffer (PBS 
with 0.02  % Tween20) and blocked at RT for 2  h with 
PBS containing 3 % BSA. After blocking, the plates were 
washed twice, 50  µL of viral lysate was added to each 
specific well, and they were incubated at RT for 3 h. The 
gp120 plates were subsequently washed three times and 
incubated with 2G12 (1.5 µg/mL) at RT for 2 h. Next, the 
plate was washed three times with ELISA wash buffer, 
and alkaline phosphatase-conjugated anti-human IgG 
(1:1000, Sigma) was added to each well and incubated 
for another 2  h. Finally, phosphatase substrate (Sigma) 
was added, and the absorbance was determined using an 
ELISA reader (Model 680 microplate reader, Bio-Rad) at 
405 nm. A standard curve was plotted using a serial dilu-
tion of purified HIV-1 SF2 gp120. The envelope content 
per virion was represented by the ratio of gp120/p24 con-
centration [38].
Envelope fusion kinetics
The fusion kinetics of WT and mutant envelope proteins 
were determined using dual split protein (DSP)-depend-
ent cell–cell fusion assays with a protocol adapted from 
Kondo et  al. [39]. Plasmids for this assay, pDSP1–7 and 
pDSP8–11, were kindly provided by Dr. Z. Matsuda, The 
University of Tokyo. Briefly, for the generation of HIV-1 
envelope-expressing cells, 293T cells in a six-well cell 
culture plate were co-transfected with pDSP1–7 and a 
plasmid expressing both envelope (Env) and EGFP. Con-
currently, TZM-bl cells (104 cells/well) were transfected 
with pDSP8–11 plasmid in a 96-well white-bottomed 
cell culture plate. After 36  h of transfection, the TZM-
bl cell media were replaced with 50 µL of fresh DMEM 
with 10  % FCS containing 60  µM of EnduRen (Pro-
mega Corporation, Madison, WI, USA), and the cells 
were incubated 2  h at 37  °C in 5  % CO2. At the end of 
the incubation, 293T cells were harvested using 0.05  % 
trypsin and resuspended at a concentration of 2  ×  106 
cells/mL in fresh medium. For co-culture, 50 µL of resus-
pended Env-DSP1–7-expressing 293T cells were trans-
ferred into the wells of CD4-CCR5-DSP8–11-expressing 
TZM-bl cells and mixed very gently several times. Renilla 
luciferase activity was measured with a luminometer at 
0, 15, 30, 45, 60, 75, 90, and 120  min time-points after 
co-culture. During co-culture, the expression level of 
envelope on the transfected cells was analyzed by stain-
ing with 2G12. The expression levels of envelope mutants 
were confirmed to be similar to that of WT envelope 
(<20 % change in MFI). The fusion percentage was calcu-
lated using the RLU value at 120 min as 100 %.
Molecular dynamic (MD) simulations of the HIV‑1 gp41 
trimer
The extracellular portion of the HIV-1JR-FL gp41 struc-
tures with and without an I37K mutation were con-
structed by using the homology modeling method with 
Molecular Operating Environment (Chemical Com-
puting Group Inc., Montreal, QC, Canada). The crystal 
structure of the HIV-1 BG505 SOSIP.664 gp140 trimer at 
a resolution of 3.1 Å (PDB code: 4TVP) [40], which con-
tains the extracellular portion of the gp41 trimer in asso-
ciation with the gp120 trimer, was used as the modeling 
template. MD simulations were performed as previously 
described to analyze changes in the structural dynamics 
of protein interaction of the surface in solution [41–45]. 
The simulations were done by the pmemd module in 
the Amber 11 program package [46] with the AMBER 
ff99SB-ILDN force field [47] and the TIP3P water model 
for simulations of aqueous solutions [48]. A non-bonded 
cutoff of 10 Å was used. Bond lengths involving hydrogen 
were constrained with SHAKE, a constraint algorithm to 
satisfy Newtonian motion [49], and the time step for all 
MD simulations was set to 2 fs. After heating calculations 
for 20  ps until 310K using the NVT ensemble, simula-
tions were executed using the NPT ensemble at 1  atm, 
at 310K, and in 150  mM NaCl for 100  ns. Root mean 
square fluctuation (RMSF) were calculated as previously 
described [41–45] to quantify the structural dynamics 
of the molecules in these MD simulations. RMSF of the 
Cα atoms were calculated to obtain information about 
the atomic fluctuations of individual amino acid resi-
dues during MD simulations [46]. The 2000 snapshots 
obtained from MD simulations of 80–100  ns were used 
to calculate RMSF. The average structures were used as 
reference structures for RMSF calculation. RMSF, which 
quantifies the differences between the average values and 
those obtained at given times of MD simulations, was 
calculated using the ptraj module in Amber, a trajectory 
analysis tool [46].
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Results
Enhanced neutralization of C34‑, SC34‑, 
and SC34EK‑resistant mutants compared with WT 
and ENF‑resistant mutants
We selected HIV-1 strain JR-FL, which is a primary 
CCR5-tropic isolate that has been classified in the tier 2 
level of neutralization sensitivity, to use as our WT for 
evaluating the neutralization sensitivity of drug-resist-
ant mutants. The Env of JR-FL is relevant to subtype B 
clinical isolates and has been used as the WT strain for 
mutagenesis analyses in many previous studies [50–52]. 
Mutants resistant to C34, SC34, and SC34EK were pre-
viously obtained by in vitro passages of the NL4-3 strain 
in the presence of each inhibitor (Additional file  1: Fig. 
S1) [53–55]. For comparison with other fusion inhibi-
tor resistant mutants, we selected three ENF resistant 
mutants V38A, Q40H, and N43D, because these muta-
tions were frequently observed in ENF treated patients 
and confer more than tenfold resistance to ENF [54, 56, 
57]. We constructed fusion inhibitor-resistant mutants 
by inserting each mutation associated with ENF, C34, 
SC34, or SC34EK resistance into the Env construct 
with a JR-FL background (pCXN-JR-FL), and the ENF-
resistant clones were designated as V38A, Q40H, and 
N43D, the C34-resistant clone was designated as C34r, 
the SC34-resistant clone was designated as SC34r, and 
the SC34EK-resistant clone was designated as SC34EKr. 
We prepared pseudoviruses with Env from JR-FL WT or 
from variants with mutations conferring fusion inhibi-
tor resistance and tested their sensitivity to the corre-
sponding fusion inhibitors (Additional file 2: Fig. S2). We 
confirmed the complete resistance to the corresponding 
inhibitors of JR-FL-based pseudoviruses with mutations 
conferring resistance to ENF, C34, SC34, or SC34EK. The 
resulting data show the successful transfer of the resist-
ance phenotype to a JR-FL background. Concerning C34 
resistance, we also constructed additional three mutants, 
I37K, N126K, and N126K/L204I, and we found that I37K 
contributed most of the resistance to C34 (Additional 
file 2: Fig. S2).
To investigate the effect on antibody-mediated HIV-1 
neutralization of mutations that confer fusion inhibitor 
resistance, we examined the sensitivity of fusion inhibi-
tor-resistant pseudoviruses to a panel of MAbs targeting 
CD4bs, V3 loop, CD4i (CD4 induced epitope), or MPER 
epitopes. We observed enhanced neutralization sensitiv-
ity of C34-, SC34-, and SC34EK-resistant viruses by the 
selected antibodies with respect to the neutralization 
sensitivity of the WT virus (Fig.  1). In contrast, two of 
the three mutations conferring ENF resistance, V38A and 
Q40H, were unable to affect the neutralization sensitivity 
by these antibodies. The N43D mutation conferring ENF 
resistance enhanced the neutralization by anti-MPER 
antibodies 4E10 (>threefold) and 10E8 (>tenfold). These 
data are comparable to those of a previous report that 
showed HR1 mutations conferring ENF resistance 
enhance the neutralization by anti-MPER antibodies 
4E10 and 2F5 [25]. In addition to the enhanced neutrali-
zation sensitivity to anti-MPER antibodies of the N43D 
mutant, we also observed an over threefold enhancement 
of neutralization by anti-V3 antibodies 0.5γ and KD247 
for this mutant (Fig. 1).
The C34r with I37K/N126K/L204I mutations was sen-
sitive to neutralization by 4E10 and 10E8 (>threefold). 
Both anti-CD4bs bnAb b12 and VRC01, potently neutral-
ized both WT and C34r mutants. Interestingly, 49G2 and 
42F9, which are non-neutralizing antibodies against the 
WT virus, were able to neutralize the C34r mutant. Fur-
thermore, the C34r mutant was more sensitive to all anti-
V3 antibodies than the WT virus.
The SC34r mutant was not sensitive to neutraliza-
tion by the anti-MPER antibodies 4E10 and 2F5 but was 
neutralized by 10E8 with a higher potency (>threefold) 
than the WT virus. The presence of E151K and K154N 
mutations in the 2F5 epitope ELDKWA may explain why 
SC34r is not sensitive to 2F5 (Additional file 1: Fig. S1). 
Enhanced neutralization by anti-CD4bs and anti-V3 anti-
bodies was observed in the SC34r mutant, similar to the 
enhanced neutralization of these antibodies in the C34r 
mutant. The SC34EKr variant had the highest enhance-
ment of neutralization sensitivity for all anti-MPER anti-
bodies as compared with other fusion inhibitor-resistant 
mutants. Although the anti-CD4bs antibody 42F9 was 
unable to neutralize the SC34EKr mutant, neutraliza-
tion enhancement in this mutant was observed for 49G2 
and all three anti-V3 antibodies (Fig. 1). For CD4i MAbs, 
subtle differences in the neutralization sensitivities were 
observed between the WT and mutants. In general, our 
observations indicate that mutations conferring fusion 
inhibitor resistance also confer enhanced neutralization 
sensitivity to the CD4bs, V3 loop, and MPER epitopes.
C34‑resistance‑conferring mutations I37K and N126K are 
critical for increasing the sensitivity to antibodies directed 
against either gp120 or gp41
To investigate the effect on the neutralization sensitivity 
of mutations conferring fusion inhibitor resistance, we 
focused on the C34r mutant that comprises three muta-
tions (I37K/N126K/L204I). The impact of the individual 
mutations in the C34r mutant on its sensitivity to anti-
bodies was analyzed by performing neutralization assays 
using antibodies targeting the CD4bs (VRC01, 49G2, and 
42F9), V3 (16G6, KD247, and 0.5γ), and MPER (10E8). 
As shown in Fig.  2a, I37K (5.9-fold) and N126K (7.2-
fold) mutants are more sensitive to VRC01 than WT, 
based on their corresponding IC50 values. However, the 
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neutralization sensitivity of the combination of these two 
mutations (I37K/N126K) was unaltered with respect to 
WT. Additionally, neutralization by VRC01 was unaf-
fected by the combinations of mutations I37K/L204I 
and N126K/L204I compared to WT. Anti-CD4bs anti-
bodies, 49G2 and 42F9, failed to neutralize WT virus, 
but the inhibition by these antibodies reached over 50 % 
against I37K, N126K, and I37K/L204I mutants. These 
results indicate that I37K and N126K are the key muta-
tions responsible for increased neutralization sensitivity 
against anti-CD4bs antibodies, and that the combination 
of these mutations with L204I caused the C34-resistant 
phenotype in C34r. Interestingly, the I37K and N126K 
mutations were unable to increase the sensitivity to all 
of these anti-CD4bs antibodies in combination, suggest-
ing that the effects of these mutations on the sensitivity 
of the viruses to anti-CD4bs antibodies were antagonized 
by each other (Fig. 2a).
To investigate the impact of sCD4 on both single and 
double mutants of C34-resistant variants, neutralization 
assays were performed with sCD4. The resulting data 
show that sensitivity to sCD4 was significantly higher in 
I37K (11-fold) and C34r (7.6-fold) mutants than in the 
WT virus. Furthermore, a slight increase in sCD4 sensi-
tivity by I37K/L204I (threefold) was observed (Fig.  2b). 
This marked increase in the sensitivity to sCD4 in the 
I37K mutant indicates that the I37K mutation is predom-
inantly responsible for the observed increase in sCD4 
sensitivity of C34-resistant variants.
Although C34r was more sensitive to anti-V3 antibod-
ies than WT (Fig. 1), single and double mutations of C34r 
did not affect its sensitivity to any of the tested anti-V3 
antibodies except 16G6 (Fig. 3a). Mutants with I37K and 
L204I showed a fivefold increase in their sensitivity to 
16G6; however, the sensitivities to KD247 and 0.5γ were 
similar between WT and mutants. This suggests that the 
combination of three mutations in C34r may act syn-
chronously to impact the neutralization profile of anti-V3 
antibodies (Fig. 3a).
The neutralization potency of the anti-MPER antibody 
10E8 was enhanced in I37K (4.5-fold) and I37K/L204I 
(fivefold) mutants compared with WT (Fig. 3b). This neu-
tralization pattern of I37K and I37K/L204I was similar to 
that of anti-CD4bs antibodies, 49G2 and 42F9 (Fig. 2a). 
These results demonstrate that the C34r mutation I37K 
plays a crucial role in the increased sensitivity to antibod-
ies directed against CD4bs and MPER, even though the 
enhanced neutralization by anti-V3 antibodies requires 
all three C34-resistance-associated mutations. In con-
trast, the N126K mutation only influences the neutraliza-
tion by anti-CD4bs antibodies.
The I37K mutation enhances the binding affinity 
of antibodies to epitopes on gp120
To investigate the mechanism of neutralization enhance-
ment, we used flow cytometry to assess the binding of 
antibodies against CD4bs (VRC01, 42F9, and 49G2) 
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gp41 Unidentified  2E8S34 >100 >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) 
MPER 4E10 2.3 2.8 (0.82) 2.6 (0.90) 0.66 (3.5) 0.58 (4.0) >50 ( - ) 0.101 (22) 
2F5 0.84 0.32 (2.6) 2.06 (0.41) 0.43 (1.9) 0.41 (2) >50 ( - ) 0.041 (21) 
  10E8 0.51 0.37 (1.4) 0.26 (2.0) 0.042 (12) 0.11 (4.7) 0.07 (7.2) 0.041 (12) 
gp120 CD4bs b12 0.011 0.026 (0.43) 0.015 (0.75) 0.022 (0.51) 0.013 (0.82) 0.027 (0.40) 0.017 (0.63) 
VRC01 0.098 0.05 (1.9) 0.035 (2.8) 0.042 (2.3) 0.024 (4) 0.051 (1.9) 0.072 (1.4) 
49G2 >100 >100 ( - ) >100 ( - ) >100 ( - ) 33 ( - ) 22 ( - ) 77 ( - ) 
82D5 >100 >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) 
42F9 >150 >150 ( - ) >150 ( - ) >150 ( - ) 28 ( - ) 21 ( - ) 
V3 0.5  14 6.8 (2.1) 5.9 (2.4) 4.6 (3.1) 2.8 (5.2) 2.3 (6.3) 2.6 (5.6) 
KD247 8.3 7.6 (1.1) 7.5 (1.1) 1.9 (4.3) 2.1 (4) 1.3 (6.2) 1.3 (6.5) 
16G6 74 >100 ( - ) >100 ( - ) >100 ( - ) 13 (5.5) 7.1 (10) 13 (5.6) 
CD4i 916B2 >100 >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) >100 ( - ) 
4E9C >100 >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) 
  17b >50 >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) >50 ( - ) 
>150 ( - ) 
Fig. 1 Neutralization sensitivities of mutants resistant to ENF, C34, SC34, or SC34EK. The neutralization sensitivities of fusion inhibitor-resistant 
mutants are shown as the average IC50 (µg/mL) of MAbs from several independent experiments. The fold change in neutralization sensitivity with 
respect to WT is presented in brackets below each IC50 values and highlighted by the following color code: yellow; 3–10-fold, red; >10 fold, and green; 
an emergence of neutralization sensitivity for MAbs that are not neutralizing to WT virus. Mutants for which calculation of fold change was not pos-
sible are presented with “–” in brackets













a  Anti CD4bs MAb
b  sCD4
I37K - 5.9 fold
N126K - 7.2 fold
I37K - 11 fold
C34r - 7.6 fold
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Fig. 2 Effect of C34 resistance-conferring mutations on the sensitivi-
ties to anti-CD4bs MAb and sCD4. Three mutations that together 
confer C34 resistance, I37K, N126K, and L204I, were examined for their 
effect on the neutralization sensitivity to anti-CD4bs MAbs, VRC01, 
49G2, and 42F9, (a) and to sCD4 (b) using single (left) and double 
(right) mutants. In each graph, the x axis represents the log con-
centration of MAbs in µg/mL and the y axis represents the percent 
inhibition compared with the corresponding no inhibitor control. The 
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I37K - 4.5 fold I37K/L204I - 5.1 fold
I37K - 5.4 fold
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Fig. 3 Effect of C34 resistance-conferring mutations on the sensitivi-
ties to MAbs against V3 and MPER. Three mutations that together 
confer C34 resistance, I37K, N126K, and L204I, were examined for their 
effect on the neutralization sensitivity to the anti-V3 MAbs, KD247, 
16G6, and 0.5γ, (a) and to the anti-MPER MAb 10E8 (b) using single 
(left) and double (right) mutants. In each graph, the x axis represents 
the log concentration of MAbs in µg/ml and the y axis represents the 
percent inhibition compared with the corresponding no inhibitor 
control. The results are shown as the means ± SEs of three independ-
ent experiments
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expressed on the cell surface and evaluated the exposure 
level of epitopes on un-triggered Env trimers (Fig.  4). A 
striking enhancement was observed for anti-CD4bs anti-
bodies, 42F9 (twofold) and 49G2 (1.6–1.7 fold), against 
C34r, I37K and I37K/L204I mutants. These mutants all 
had the I37K mutation, suggesting that the increased 
binding affinity of 42F9 and 49G2 to viruses with I37K 
enhances the neutralization by these antibodies (Fig. 2a). 
N126K, the other C34-resistant mutation that is criti-
cal for enhanced neutralization, did not affect the anti-
body binding, and, instead, it abrogated the enhancement 
effect of I37K in the I37K/N126K mutant. This finding 
suggests that the N126K mutation enhances neutraliza-
tion by a mechanism other than an increase in the affin-
ity between the envelope and the antibody. We observed 
some increase in VRC01 binding, but this occurred in 
the absence of any correlation with neutralizing sensitiv-
ity (Fig. 4). This lack of correlation between neutralization 
sensitivity and binding affinity indicates that the enhanced 
neutralization sensitivity of I37K and N126K to VRC01 is 
mediated by some other unknown mechanism (Fig. 2a).
The I37K mutation also slightly affected the binding 
of anti-V3 antibodies, but the effect was marginal com-
pared with that of anti-CD4bs antibodies, 42F9 and 
49G2 (Fig.  4). The slight increase in the binding affinity 
of anti-V3 antibodies in I37K mutants may contribute to 
the enhanced neutralization of C34-resistant mutants. 
Anti-MPER antibodies were omitted from this analysis 
because of the MPER epitope inaccessibility to these anti-
bodies in un-triggered envelope [58].
These results indicate that the I37K mutation induces 
a conformational change in the envelope trimer, which 
Fig. 4 Binding of antibodies to untriggered envelope trimers. The effect of fusion inhibitor resistance-conferring mutations on the binding of 
anti-CD4bs MAbs, VRC01, 49G2, and 42F9, and of anti-V3 MAbs, KD247, 16G6, and 0.5γ, was determined by performing flow cytometry on 293T cells 
expressing mutant envelopes. The geometric MFI was calculated and normalized by the MFI of 2G12. The changes in antibody binding levels are 
presented as the fold change of binding with respect to WT. The dash line represents the change in antibody binding (fold change = 1). The results 
are shown as the means ± SEs of three replicas
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results in the enhancement of antibody binding owing 
to improved accessibility to epitopes on gp120. The 
I37K mutation had a drastic effect on the binding affin-
ity of the anti-CD4bs antibodies 42F9 and 49G2, and 
this may be correlated with the enhanced neutralization 
of C34-resistant viruses by these antibodies. However, 
mechanisms other than an increase in the binding affinity 
are likely responsible for the enhanced neutralization by 
VRC01 and anti-V3 antibodies.
Influence of mutations in gp41 on the infectivity 
and envelope content of mutant virions
It has been suggested that the amount of envelope con-
tent per HIV-1 virion may affect the viral infectivity and 
neutralization sensitivity [38, 59, 60]. It was reported that 
a 10- to 14-fold rise in the envelope content in an SIV 
model may lead to a 20- to 500-fold increase in infectiv-
ity, which results in resistance to neutralization [59, 61, 
62]. Therefore, we investigated the effect of C34-resist-
ance-associated mutations on the viral infectivity and 
envelope content on the virion surfaces.
As shown in Fig. 5a, the infectivity of the C34r mutant 
was 1000-fold lower than of the WT, which can be com-
pared with the mild effect on infectivity of mutations 
conferring ENF resistance. The I37K mutant, as well as 
combination mutants that included I37K, also showed a 
significant decrease in infectivity compared with the WT, 
similar to the C34r mutant, suggesting that I37K is the 
major mutation responsible for the reduced infectivity. 
Two ENF-resistant mutants, N43D and Q40H, showed 
low infectivity compared with WT (approximately ten-
fold), but the infectivity of the V38A mutant was at the 
same level as the WT. These data demonstrate that I37K 
is critical for C34 resistance in JR-FL, but its presence 
imposes a significant fitness cost (Fig.  5a). The effect of 
N126K on C34 resistance and its fitness cost were lower 
than that of I37K. We are unable to comment on the role 
of L204I in fitness because it was evaluated by single 
round infection assay in this study (14).
We observed a 7- to 11-fold decrease in the envelope 
content of I37K, N126K, and L204I mutants as compared 
with WT (Fig.  5b). C34r also showed a 14-fold reduc-
tion in the amount of envelope per virion. There was not 
a consistent pattern in the Env content for combination 
of these three mutations; I37K/N126K had an over two-
fold increase in envelope per p24, whereas N126K/L204I 
showed an approximately twofold decrease. The envelope 
concentration for I37K/L204I was similar to the envelope 
content of L204I (6.5-fold decreases). This change in the 
envelope content on the surfaces of I37K and C34r pseu-
doviruses may be partially responsible for their reduced 
infectivity and higher sensitivity to neutralization. The 
Fig. 5 Comparison of infectivity and envelope content among fusion inhibitor-resistant mutants. a The infectivity levels of ENF-resistant mutants, 
V38A, N43D, and Q40H, and of C34-resistant mutants, I37K, N126K, L204I, I37K/N126K, I37K/L204I, N126K/L204I, and C34r, are shown. The TCID50 and 
p24 concentrations were determined by single round infection assays using TZM-bl cells and ELISAs, respectively. Infectivity is shown as the TCID50/
p24 amount ratio. b The envelope content per virion was compared among C34 resistance mutants. The concentrations of envelope and p24 in 
pseudovirus stocks were determined by ELISAs. As negative control pseudovirus expressing no envelope was used. The envelope content is shown 
as the envelope/p24 amount ratio. The results are expressed as the means ± SEs of three independent experiments. Asterisks correspond to values 
that are statistically different from those of the WT (p < 0.05 as calculated using the Mann–Whitney U test)
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amount of envelope on virion surfaces and its impact on 
neutralization sensitivity still awaits clarification [38, 59, 
60]. Additionally, another limitation of this data is that 
they measure the monomeric gp120 from lysed viruses, 
but the number of functional trimers may influence the 
neutralization sensitivity.
Slow fusion kinetics of C34r and I37K mutants
It has been suggested that enhancement of neutralization 
by anti-MPER antibodies is due to slower fusion kinetics, 
which lead to prolonged exposure of the epitope [25, 63–
65]. To test this hypothesis, we performed fusion assays 
for I37K, N126K, N126K/L204I, and C34r mutants. As 
shown in Fig. 6, both I37K and C34r have reduced fusion 
kinetics with respect to WT. However, no such change 
was apparent for N126K or N126K/L204I mutants 
(Fig. 6). These data are consistent with the enhanced neu-
tralization sensitivity of C34r and I37K mutants to 10E8 
(Fig. 3b).
Large fluctuations in interfaces between gp41 and gp120 
in Env trimer with I37K mutation
Our data suggest that the I37K mutation in gp41 has 
global effects on the physical properties of the gp120/
gp41 trimer. The amino acid residue at position 37 of 
gp41 is located at the interface between gp41 and gp120 
in the Env trimer [66]. To gain structural insights into 
the biological effects of the I37K mutation, we con-
ducted structural modeling and MD simulations of the 
extracellular portion of HIV-1JR-FL gp41 trimer with 
and without an I37K substitution. Using 2000 snap-
shots of the structures from the last 20 ns of each MD 
Fig. 6 Fusion kinetics of C34-resistant mutants. The effects of N126K, N126K/L204I, C34r, and I37K mutations on fusion kinetics were determined by 
dual split protein (DSP)-dependent cell–cell fusion assays. Renilla luciferase activity, which was detected in fused cells, was monitored periodically, 
and fusion is expressed as the percentage of fusion after 120 min. The results are shown as the means ± SEs of at least five replicas
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simulation, we examined the atomic fluctuations of 
individual amino acid residues by calculating the RMSF 
of the Cα atoms [46]. The results revealed a marked 
increase in the RMSFs of the gp41 with I37K muta-
tions (Fig. 7a). Notably, RMSFs at positions 20–65 in the 
N-terminal portions of the gp41 extensively increased 
in all three protomers consisting of the gp41 trimer 
with the I37K mutation (Fig. 7a, double-headed arrows). 
Notably, this region is located in the protein–protein 
interface between gp41 and gp120 in the Env trimer 
(Fig.  7b) [40]. The results suggest that the I37K muta-
tion induces augmentation of structural fluctuations 
prominently in the interfaces between gp41 and gp120 
in the Env trimer.
Polyclonal IgG from HIV‑1 infected patients can neutralize 
C34r better than WT JR‑FL
To clarify the effect of C34-resistant mutations for the 
neutralization sensitivity against plasma IgG from HIV-1 
infected patients, we examined the neutralization sensi-
tivities of the HIV-1 tier 1 virus BaL, the tier 2 virus JR-FL 
(WT), and the C34r mutant. Among 11 samples, IgG 
from ten samples (91 %) neutralized BaL, IgG from four 
samples (36 %) neutralized WT, and IgG from eight sam-
ples (73  %) neutralized the C34r mutant (Table  1). The 
higher frequency of neutralization for C34r suggests that 
the contribution of non-neutralizing antibodies, such 
as antibodies against the CD4bs, became neutralizing 
against the JR-FL variant containing the C34r mutation 
Fig. 7 MD simulation of the HIV-1 gp41 trimer. Molecular modeling and MD simulation of the extracellular portion of the HIV-1 JR-FL gp41 trimer 
with and without a I37K mutation were performed using modules in the Molecular Operating Environment and the AMBER 11 program package 
[46]. a The distribution of the RMSFs of three protomers consisting of the gp41 trimer. Double-arrow heads indicate regions between positions 
20 and 65 in protomers 1, 2, and 3. b Structures of the extracellular portion of the HIV-1 JR-FL gp41 trimer with and without a I37K mutation. The 
structures at 100 ns of MD simulations are shown. The amino acid residues between positions 20 and 65 in protomers 1 (red), 2 (blue), and 3 (green) 
are highlighted
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(Table 1). The high rate of neutralization by patient IgG 
samples indicates that the C34r mutant is sensitive to 
antibodies circulating in HIV-infected patients in vivo.
Discussion
Here, we report the enhanced neutralization sensitiv-
ity to anti-CD4bs, anti-V3, and anti-MPER antibodies of 
HIV-1 variants that are resistant to the fusion inhibitors 
C34, SC34, and SC34EK. We have identified I37K in the 
HR1 region of gp41 as a key mutation for C34 resistance, 
for the exposure of gp120 epitopes, and for slowing down 
the fusion process, resulting in enhanced neutralization 
sensitivity of variants with this mutation. The results of a 
molecular dynamic simulation support the effect of I37K 
mutation on enhanced neutralization sensitivity, which is 
indicated by a fluctuation of the gp41 trimer structure.
Early investigation of the MAb sensitivity of ENF-
resistant mutants was performed using YU-2 with ENF-
resistance-conferring mutations and antibodies 2G12 
(anti-glycan), 17b, 48D (anti-CD4i), b12 (anti-CD4bs), 
4E10, and 2F5 (anti-MPER) [25]. They found that anti-
MPER antibodies enhanced the neutralization sensitiv-
ity of YU-2 containing the ENF-resistance-conferring 
mutations G36D or V38  M. Here, we employed several 
broad and conventional antibodies targeting different 
epitopes against fusion inhibitor-resistant mutants in a 
JR-FL background and found that mutations in gp41 con-
ferring fusion inhibitor resistance affected the sensitivity 
of the viruses to antibodies against epitopes on gp120. 
The bnAbs, namely VRC01 and 10E8, were more potent 
against fusion inhibitor-resistant mutants. Notably, the 
tier 2 virus JR-FL mutants containing a single mutation of 
I37K or N126K in gp41 could both be neutralized by anti-
bodies 42F9 and 49G2, which target CD4bs, even though 
these antibodies were thought to only be capable of neu-
tralizing tier 1 strains [26]. The emergence of neutraliza-
tion sensitivity to these conventional antibodies suggests 
that fusion inhibitor-resistant variants are easily neutral-
ized by the antibodies frequently induced in patients, as 
evidenced by the neutralization of C34-resistant variants 
with IgG samples from patients infected with HIV. The 
drug-resistant mutants that evolve against fusion inhibi-
tor stress usually confer resistance independent of the 
envelope context and can be used as signature sequences 
[6]. Thus, it is likely that the humoral immune system of 
HIV-1-infected patients receiving a fusion inhibitor can 
counter the emerging fusion inhibitor-resistant mutants. 
A previous study reported that a point mutation in gp120 
makes tier 2 viruses that are similarly sensitive to anti-
bodies as tier 1 viruses [67]. Our data indicate that the 
mutations in gp41 can make tier 2 viruses sensitive to 
otherwise non-neutralizing antibodies.
HIV-1-infected individuals possess antibodies against 
the V3-loop epitope of envelope protein [68]. We found 
that C34-, SC34-, and SC34EK-resistant mutants were 
each more sensitive to all the anti-V3 antibodies than the 
WT virus. This indicates that mutations in gp41 affect 
the antigenic properties of the V3- loop. A previous study 
reported that mutations in the gp41 fusion peptide region 
confer resistance to CCR5 antagonists, which inhibits the 
interaction of the V3 loop with CCR5 [69]. Conversely, 
mutations in the V3 loop influence the fusion process 
and fusion inhibitor binding [63]. Our findings, together 
with these previous observations, indicate that there is a 
specific functional interaction between the amino acids 
of the V3 loop and gp41 [63, 69]. Further study of gp41 
mutations in the modulation of co-receptor binding site 
will shed light on the molecular interplay between co-
receptor binding and progress towards fusion.
Our neutralization assay data show that I37K is the key 
mutation for the observed enhancement in neutraliza-
tion sensitivity. Furthermore, compared with the WT, the 
N126K mutant has improved neutralization sensitivity 
to CD4bs MAbs. A previous study suggested that I37K 
in the HR1 interferes with the binding of C34 and that 
N126K in the HR2 enhances the intra-gp41 binding of 
HR1 and HR2 compared with C34 [14]. Our results sug-
gest that these two mechanisms of C34 resistance also 
affect the neutralization sensitivity of the virus. However, 
pseudoviruses containing both I37K and N126K muta-
tions showed neutralization sensitivities that are similar 
to those of WT. This indicates that the I37K and N126K 
mutations antagonize the effects on neutralization 
Table 1 Neutralization sensitivity (IC50) of  BaL (tier 1), 
JR-FL (tier 2), and C34r mutants by purified IgG from HIV-1 
infected patients
IC50 of purified IgGs from HIV-1 infected patients against pseudoviruses with 
envelope from BaL, JR-FL (WT) and C34-resistant mutants were measured using 
TZM-bl cells
Patient ID IC50 (µg/mL)
BaL JR‑FL C34r
Patient 1 27 >300 >300
Patient 2 119 >300 74
Patient 3 114 >300 190
Patient 4 46 240 61
Patient 5 124 >300 >300
Patient 6 >300 >300 >300
Patient 7 178 >300 8.4
Patient 8 11 30 48
Patient 9 6 66 46
Patient 10 18 >300 161
KTS376 9 45 70
Total neutralized 91 % 36 % 73 %
Page 13 of 16Alam et al. Retrovirology  (2016) 13:70 
sensitivity of each other. The effect of I37K, which 
exposes epitopes for neutralization, may be countered by 
N126K, which stabilizes the gp41 structure by enhancing 
the binding of HR1 and HR2. Further structural analysis 
is required to clarify this antagonistic mechanism.
The L204I mutation is one of the three mutations in 
C34r, and this mutation is commonly observed in variants 
that are resistant to C34 derivatives (Additional file 1: Fig. 
S1) [14, 15]. It makes up the tyrosine-dependent sort-
ing signal in the gp41 cytoplasmic domain and enhances 
viral replication [14]. Of the antibodies we tested, a single 
L204I substitution appeared to only affect the neutraliza-
tion sensitivity to the anti-V3 antibody 16G6. The L204I 
mutation significantly contributed to neutralization sen-
sitivity when it was combined with other C34-resistance-
associated mutations, I37K and N126K. As mentioned 
earlier, I37K and N126K mutations enhanced the neutral-
ization sensitivity compared with that of WT; however, 
this effect was antagonized by the combination of I37K 
and N126K mutations. Hence, in addition to I37K and 
N126K, L204I likely also has functional importance.
The results of flow cytometry analyses of antibody 
binding indicate that I37K and N126K mutations have 
different impacts on untriggered cell surface envelope 
proteins. Anti-CD4bs antibodies 42F9 and 49G2 bound 
to the I37K mutant better than they did to the N126K 
mutant, even though the neutralization sensitivities of 
these mutants to anti-CD4bs antibodies were similar. 
Additionally, the sensitivity to sCD4 was higher for the 
I37K mutant than it was for the N126K mutant. These 
results suggest that the I37K mutation may change the 
Env structure to an open conformation, in which anti-
bodies can access the epitopes that are hidden inside in 
the closed conformation [70]. The findings from our MD 
simulation of the gp41 trimer support this hypothesis. 
Our study reveals that the I37K mutation can increase the 
structural fluctuations of gp41 protomers, prominently 
those in the regions corresponding to the gp41–gp120 
interfaces in Env trimer. Because structural fluctuations 
of the protein play key roles in its molecular interactions 
[71–73], it is possible that the increases in the fluctua-
tions of the gp41–gp120 interfaces cause an attenuation 
of the structural compaction and stability of the gp120/
gp41 trimer. Such changes in turn would open otherwise 
sterically hindered neutralization epitopes of gp120 and 
gp41. Unfortunately, the mechanism by which the N126K 
mutation enhances neutralization sensitivity is unclear. 
It is possible that N126K may reduce other structural 
interference to epitope access on the virion surface dur-
ing the viral entry step. The lack of relationship between 
the neutralization sensitivity and the envelope–antibody 
binding may be owing to antigenic differences between 
the envelope expressed on the cell surface and the virion 
surface, as observed in previous investigations [37, 74].
Another effect of gp41 mutations was reduced viral 
infectivity and envelope content especially for mutants 
bearing I37K mutation. Infectivity and envelope con-
tent can be affected by enhanced gp120 shedding due 
to destabilization of the interaction of gp120 and gp41 
[75]. However, envelope content on virion surface did 
not correlate with envelope expression level on cell sur-
face (Additional file  3: Fig. S3). Moreover, our prelimi-
nary analysis of spontaneous gp120 shedding indicated 
that most of gp120 was maintained on the surface of 
cells expressing WT and mutant envelopes, but was not 
released to supernatant (Additional file  4: Fig. S4). Fur-
ther research is required to clarify the mechanism of 
reduced viral infectivity and envelope content.
Unlike ENF resistant mutations C34-, SC34- and 
SC34EK-resistant mutations have not been studied in 
clinical setup, marking a major limitation of current 
study. The mutations obtained by in vitro passages, espe-
cially I37K, which has significantly decreased infectivity, 
may be disadvantageous to viral replication in vivo. How-
ever, occurrence of N126K mutation has been observed 
in ENF-treated patients [53], suggesting that these muta-
tions conferring resistance to C34 derivative fusion 
inhibitors may arise in HIV-1-infected patients.
Conclusions
HIV-1 envelope is known for its hypervariability, glycan 
shield, conformational dynamics, and covered conserved 
regions, which make it one of the most complex proteins 
known to date [66, 76]. These complex conformational 
dynamics make it difficult to understand the functions 
of the HIV-1 envelope based solely on rigid structure or 
biochemical analyses [77]. Thus, mutational analyses, 
especially those developed against drug responses, have 
and will provide important insights into the dynamics 
of envelope glycoprotein [67, 78]. In summary, here, we 
report the enhancement of neutralization sensitivity in 
the next-generation fusion inhibitor-resistant mutants 
to neutralizing antibodies. We observed that, along with 
bnAbs, conventional patient-derived IgGs could neutral-
ize the tested fusion inhibitor-resistant mutants. We have 
also identified the impact of the I37K and N126K muta-
tions on epitopes in both gp120 and gp41. The results 
from our attempt to understand the mechanism respon-
sible for the observed neutralization sensitivity changes 
indicate that the conformational unmasking of envelope 
glycoprotein affects the neutralization sensitivity in a very 
complex manner. Recent advances in the exploration of 
bnAbs indicate that, in the near future, HIV-1 research-
ers will be looking for drugs to administer in combina-
tion with neutralizing antibodies. In past decades, several 
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fusion inhibitors have been designed based on different 
parameters, but very few have been tested in human sub-
jects. We suggest that next-generation fusion inhibitors 
in combination with antibodies should be considered 
as the next-generation combined anti-retroviral therapy 
regimen.
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N126K/L204I) and the related double and single mutants, N126K/L204I, 
N126K, and I37K (upper right graph). Mutants, SC34r and SC34EKr, were 
examined for sensitivity to SC34 and SC34EK, respectively (lower graphs). 
In each graph, the x-axis represents the log concentration of the fusion 
inhibitor in nM and the y-axis represents the percent inhibition compared 
with the corresponding no inhibitor control. The results are shown as the 
means ± standard errors of three independent experiments.
Additional file 3: Fig. S3. Reactivity of antibodies, VRC01, 42F9, 49G2, 
b12, KD247, 16G6, 0.5γ and 2G12 to WT and mutant envelopes. Reactiv-
ity of antibodies to envelopes was analyzed using flow cytometer, and 
shown as MFI. Cells expressing Env from SIVsmE543-3 was used as a 
negative control (SIV).
Additional file 3: Fig. S4. Spontaneous gp120 shedding from cell 
surface. The susceptibility of gp41 mutants to spontaneously shed gp120 
was determined by flow cytometry and ELISA as described previously [79]. 
Briefly, culture medium of transiently transfected envelope expressing 
cells was exchanged for fresh medium containing Brefeldin A (BioLegend) 
and 0.2 % Sodium azide. Cells were then incubated for 15 h at 37˚C, 5 % 
CO2. (a) Level of envelope expression before and after incubation was 
compared by staining with 2G12. (b) Amount of gp120 released during 
incubation was determined by gp120 capture ELISA. As a positive control, 
cells expressing WT envelope was incubated with 20 µg/ml sCD4, which 
trigger gp120 shedding. Cells expressing SIV Env (SIV) and no Env (No 
Env) were used as negative control. The results are shown as the means ± 
standard errors of four replicas.
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